Showing 581 - 600 results of 1,061 for search '"lymphoma"', query time: 0.08s Refine Results
  1. 581
  2. 582

    Fatal Hepatocellular Carcinoma in a Patient with Occult Hepatitis B Virus Infection following the Administration of R-CHOP for Diffuse Large B-Cell Lymphoma by Vincenzo Pitini, Massimo Rizzo, Carmela Arrigo, Patrizia Mondello, Giuseppe Altavilla

    Published 2012-01-01
    “…We present the case of a patient with a diffuse large B-cell non-Hodgkin lymphoma and OBI who developed a hepatocellular carcinoma with a fulminant clinical course following the administration of rituximab plus CHOP.…”
    Get full text
    Article
  3. 583
  4. 584
  5. 585
  6. 586
  7. 587
  8. 588

    Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas by Luis F. Porrata, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Stephen M. Ansell, William J. Hogan, Svetomir N. Markovic

    Published 2010-01-01
    “…Natural killer cells at day 15 (NK-15), after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT), is a prognostic factor for overall survival (OS) and progression-free survival (PFS) in non-Hodgkin lymphoma (NHL). The potential role of the immunologic (homeostatic) environment affecting NK-15 recovery and survival post-APHSCT has not been fully studied. …”
    Get full text
    Article
  9. 589

    Concurrent Liver Hodgkin Lymphoma and Nodular Regenerative Hyperplasia on an Explanted Liver with Clinical Diagnosis of Alcoholic Cirrhosis at University Hospital Fundación Santa Fe de Bogotá by R. López, L. Barrera, A. Vera, R. Andrade

    Published 2014-01-01
    “…Liver involvement by Hodgkin lymphoma (HL) is well documented. However, secondary liver failure to this neoplastic process is rare and usually presents late in the course of the disease. …”
    Get full text
    Article
  10. 590

    Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma by Narendranath Epperla, Loretta J. Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, Kim Saverno

    Published 2025-01-01
    “…Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adults ineligible for autologous stem cell transplantation. …”
    Get full text
    Article
  11. 591
  12. 592

    Nomogram model and risk score predicting overall survival and guiding clinical decision in patients with Hodgkin’s lymphoma: an observational study using SEER population-based data by Yue Yang, Shang Li, Xiao Zhu, Yi Kong, Mingtao Zhang, Xiangping Liang, Zherui Zhang, Shuzhen Tan, Yingqi Li, Yueyuan Zhong, Yingqi Shao, Jiayi Xu, Zesong Li

    Published 2022-06-01
    “…We discovered that Derived American Joint Committee on Cancer (AJCC) Stage Group, lymphoma subtype, radiotherapy and chemotherapy were four independent risk factors affecting the prognosis of HL patients. …”
    Get full text
    Article
  13. 593

    Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom’s Macroglobulinemia by D. Kazmierski, M. L. Palomba, C. Barsigian

    Published 2017-01-01
    “…We present a case illustrating the utility of MYD88 status in distinguishing atypical forms of WM from marginal zone lymphoma (MZL) and in selecting second-line therapy with ibrutinib. …”
    Get full text
    Article
  14. 594
  15. 595

    Central nervous system B-cell lymphoma in a patient diagnosed with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids: A case report by Evangelos Koumasopoulos, Evangelia-Anna Spiteri, Aigli G Vakrakou, Panagiotis Toulas, Georgios Velonakis, George Stranjalis, Leonidas Stefanis, Maria-Eleptheria Evangelopoulos, Maria Anagnostouli

    Published 2025-01-01
    “…This is a case presentation of a primary central nervous system B-cell lymphoma in a 69-year-old woman with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids and chronic immunosuppressive treatment. …”
    Get full text
    Article
  16. 596
  17. 597
  18. 598
  19. 599
  20. 600